source
- FDA accepts supplemental NDA for taletrectinib targeting ROS1‑positive lung cancerThe U.S. Food and Drug Administration has accepted a supplemental New Drug Application for taletrectinib, a targeted therapy aimed at patients with ROS1‑positive non‑small cell lung cancer. The fi…
- Administration releases detailed report on most-favored-nation drug pricing, projects $529 billion savingsThe White House Council of Economic Advisers released its most detailed analysis yet of the administration's most-favored-nation drug pricing policy. The report defines the MFN pricing approach, w…